Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHAR | US
-0.06
-0.74%
Healthcare
Biotechnology
30/06/2024
04/10/2024
8.04
8.16
8.16
8.04
Pharming Group N.V. a biopharmaceutical company develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States Europe and internationally. The company's commercialized product is RUCONEST a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105 an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research development manufacturing and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden the Netherlands.
View LessValue Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
63.6%1 month
51.2%3 months
71.7%6 months
76.1%-
169.49
2.61
0.63
0.32
76.69
1.99
-
-5.04M
545.40M
545.40M
-
-4.21
-61.50
35.00
-6.33
0.58
0.01
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.12
Range1M
1.92
Range3M
2.35
Rel. volume
0.38
Price X volume
19.20K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.42 | 593.84M | 0.95% | n/a | 50.92% |
Oculis Holding AG Ordinary shares | OCS | Biotechnology | 13.2 | 551.04M | 8.20% | n/a | 1.19% |
Revance Therapeutics Inc | RVNC | Biotechnology | 5.22 | 543.82M | 0.58% | n/a | -378.95% |
UroGen Pharma Ltd | URGN | Biotechnology | 12.7 | 534.85M | 0.95% | n/a | 326.69% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 9.97 | 518.14M | -2.92% | n/a | 2.32% |
Third Harmonic Bio Inc. | THRD | Biotechnology | 12.52 | 514.54M | -0.71% | n/a | 1.40% |
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 76.69 | 0.76 | Expensive |
Ent. to Revenue | 1.99 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.61 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 71.73 | 74.67 | Par |
Debt to Equity | 0.63 | -1.82 | Expensive |
Debt to Assets | 0.32 | 0.26 | Expensive |
Market Cap | 545.40M | 3.73B | Emerging |